Left ventricular ejection fraction determined with the simulation of a very low-dose CZT-SPECT protocol and an additional count-calibration on planar radionuclide angiographic data.


Journal

Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology
ISSN: 1532-6551
Titre abrégé: J Nucl Cardiol
Pays: United States
ID NLM: 9423534

Informations de publication

Date de publication:
Oct 2019
Historique:
received: 29 10 2018
accepted: 21 12 2018
pubmed: 1 3 2019
medline: 21 10 2020
entrez: 1 3 2019
Statut: ppublish

Résumé

To determine whether the left ventricular ejection fractions (EFs), measured on a high-sensitivity CZT single photon emission computed tomography (SPECT)-camera with a 70% reduction in recording times and a prevention of EF overestimation through an additional count-calibration, are concordant with reference EF from planar radionuclide angiography (2D-RNA). An additional 10-minute CZT-SPECT recording was performed in patients referred to 2D-RNA for cardiomyopathy (n = 23) or chemotherapy monitoring (n = 50) with an in vivo red blood cell labeling with 850 MBq [Formula: see text]. The EF, obtained from CZT-SPECT with 100% (SPECT100) or 30% (SPECT30) projection times and with a SPECT-count calibration on the 2D-RNA counts of corresponding cavity volumes, were compared to EF from 2D-RNA. Strong and equivalent relationships were documented between the EF from 2D-RNA and the calibrated EF from SPECT100 (y = 0.89x + 6.62; R Left ventricular EF may be determined on a high-sensitivity CZT-camera, a 70% reduction in injected activities, and an additional count-calibration for further enhancing the concordance with 2D-RNA values.

Identifiants

pubmed: 30815836
doi: 10.1007/s12350-019-01619-w
pii: 10.1007/s12350-019-01619-w
doi:

Substances chimiques

Antineoplastic Agents 0
CdZnTe 0
Cadmium 00BH33GNGH
Zinc J41CSQ7QDS
Tellurium NQA0O090ZJ

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1539-1549

Commentaires et corrections

Type : CommentIn

Références

J Nucl Cardiol. 2018 Dec;25(6):2016-2023
pubmed: 28512723
Clin Physiol Funct Imaging. 2015 Nov;35(6):418-24
pubmed: 24980073
J Nucl Cardiol. 2010 Jun;17(3):427-34
pubmed: 20151236
Ann Nucl Med. 2008 Apr;22(3):171-6
pubmed: 18498031
Curr Cardiol Rep. 2017 Apr;19(4):31
pubmed: 28315122
J Nucl Cardiol. 1999 Sep-Oct;6(5):498-506
pubmed: 10548145
J Nucl Cardiol. 2018 Aug 17;:null
pubmed: 30120749
J Nucl Cardiol. 2016 Jun;23(3):348-61
pubmed: 26956876
Ann Oncol. 2012 Oct;23 Suppl 7:vii155-66
pubmed: 22997448
J Nucl Cardiol. 2014 Apr;21(2):384-96
pubmed: 24366823
Eur J Nucl Med Mol Imaging. 2008 Apr;35(4):851-85
pubmed: 18224320
J Nucl Med. 1996 Nov;37(11):1795-9
pubmed: 8917177
Eur J Nucl Med Mol Imaging. 2013 Aug;40(8):1163-70
pubmed: 23632963
J Nucl Med. 2012 Apr;53(4):584-91
pubmed: 22393224
Br J Radiol. 2008 Apr;81(964):270-4
pubmed: 18250120
J Nucl Cardiol. 2011 Aug;18(4):642-9
pubmed: 21647809
Eur J Nucl Med Mol Imaging. 2014 Mar;41(3):522-8
pubmed: 24202049
J Nucl Med. 2016 Sep;57(9):1370-5
pubmed: 27127220
Nucl Med Commun. 2005 Apr;26(4):351-9
pubmed: 15753795
J Nucl Med. 2012 Dec;53(12):1897-903
pubmed: 23139084
Ann ICRP. 2013 Feb;42(1):1-125
pubmed: 23141687
J Nucl Cardiol. 2005 Jan-Feb;12(1):78-85
pubmed: 15682368
J Nucl Cardiol. 2016 Oct;23(5):1128-1138
pubmed: 26231888
J Nucl Cardiol. 2007 Jul;14(4):544-9
pubmed: 17679063
Eur J Nucl Med Mol Imaging. 2015 Jun;42(7):1004-11
pubmed: 25711177
J Nucl Cardiol. 2018 Feb;25(1):249-256
pubmed: 27677613

Auteurs

Hubert Tissot (H)

Department of Nuclear Medicine and Nancyclotep Molecular Imaging Platform, CHRU-Nancy, Université de Lorraine, 54000, Nancy, France.

Véronique Roch (V)

Department of Nuclear Medicine and Nancyclotep Molecular Imaging Platform, CHRU-Nancy, 54000, Nancy, France.

Olivier Morel (O)

CHU-Besançon, Université de Franche-Comté, Service de Médecine Nucléaire, 25000, Besançon, France.

Nicolas Veran (N)

Department of Nuclear Medicine, CHRU-Nancy, 54000, Nancy, France.

Mathieu Perrin (M)

Department of Nuclear Medicine, CHRU-Nancy, 54000, Nancy, France.

Marine Claudin (M)

Department of Nuclear Medicine, CHRU-Nancy, 54000, Nancy, France.

Antoine Verger (A)

Department of Nuclear Medicine and Nancyclotep Molecular Imaging Platform, CHRU-Nancy, Université de Lorraine, 54000, Nancy, France.
INSERM, UMR 1254, Université de Lorraine, 54000, Nancy, France.

Gilles Karcher (G)

Department of Nuclear Medicine and Nancyclotep Molecular Imaging Platform, CHRU-Nancy, Université de Lorraine, 54000, Nancy, France.

Pierre-Yves Marie (PY)

Department of Nuclear Medicine and Nancyclotep Molecular Imaging Platform, CHRU-Nancy, Université de Lorraine, 54000, Nancy, France.
INSERM, UMR 1116, Université de Lorraine, 54000, Nancy, France.

Laetitia Imbert (L)

Department of Nuclear Medicine and Nancyclotep Molecular Imaging Platform, CHRU-Nancy, 54000, Nancy, France. l.imbert@chu-nancy.fr.
INSERM, UMR 1254, Université de Lorraine, 54000, Nancy, France. l.imbert@chu-nancy.fr.
Médecine Nucléaire, Hôpital de Brabois, CHRU-Nancy, Allée du Morvan, 54500, Vandoeuvre-Les-Nancy, France. l.imbert@chu-nancy.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH